EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Electrophysiological effects of encainide and its metabolites in 11 patients


Journal of Cardiovascular Pharmacology 7(6): 1077-1082
Electrophysiological effects of encainide and its metabolites in 11 patients
Encainide is a new antiarrhythmic class IC agent. Eleven patients were given 1 mg/kg of encainide i.v. over a 15-min period. Electrophysiological studies were done before and l h after drug administration. Blood levels of encainide and its principle metabolites O-demethyl-encainide, 3 metoxy-O-demetyl-encainide and N-demethyl-encainide were measured serially after drug administration. Heart rate, blood pressure, and conduction intervals were monitored. Sixty minutes after drug administration there was a marked increase of the QRS, PA, AH, and HV intervals of 28.1% (p less than 0.01), 17.2% (p less than 0.01), 22.4% (p less than 0.01), and 32.2% (p less than 0.01), respectively, and a slight increase of the Wenckebach cycle length of 8% (p less than 0.05). BP, RR, QT, CSNRT, ESACT, ERP, and FRP did not vary significantly. The HV interval already was increased significantly 2 min after drug administration, while AH was not increased until 15 min after drug administration. The average blood levels of encainide and ODE 60 min after drug administration were 0.410 +/- 0.12 and 0.176 +/- 0.09 microgram/ml, respectively (mean +/- SE of the mean). There was a positive correlation between the increase of the AH and the blood level of ODE, which points out the importance of prolonged electrophysiological studies when testing drug with possibly active metabolites.


Accession: 005349566

PMID: 2418291

DOI: 10.1097/00005344-198511000-00010



Related references

The effects of encainide and its major metabolites, O-demethyl encainide and 3-methoxy-O-demethyl encainide, on experimental cardiac arrhythmias in dogs. Journal of Cardiovascular Pharmacology 7(3): 449-457, 1985

Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man. Circulation 77(2): 380-391, 1988

Antiarrhythmic activity electrocardiographic effects and pharmacokinetics of the encainide metabolites o demethylencainide and 3 methoxy o desmethyl encainide in man. Circulation 77(2): 380-391, 1988

Intravenous and oral encainide: electrophysiological effects in patients with paroxysmal reciprocating supraventricular tachycardia. Giornale Italiano di Cardiologia 15(5): 533-542, 1985

Electrophysiological effects of encainide and its metabolites in normal canine Purkinje fibers and Purkinje fibers surviving infarction. Canadian Journal of Physiology and Pharmacology 67(7): 751-756, 1989

Myocardial uptake of encainide and its two major metabolites, O-demethyl encainide and 3-methoxy-O-demethyl encainide, in the dog. Journal of Cardiovascular Pharmacology 6(4): 663-667, 1984

Myo cardial uptake of encainide and its 2 major metabolites o demethyl encainide and 3 methoxy o demethyl encainide in the dog. Journal of Cardiovascular Pharmacology 6(4): 663-667, 1984

Possible contribution of encainide metabolites to the long-term antiarrhythmic efficacy of encainide. American Journal of Cardiology 51(7): 1182-1188, 1983

Increased incidence of heart block induced by combined encainide encainide metabolites and verapamil in dogs. American Heart Association Monograph: Iii-270, 1983

Electrophysiological effects of encainide in man. Archives des Maladies du Coeur et des Vaisseaux 77(6): 707-711, 1984